Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax.

Slides:



Advertisements
Similar presentations
Future challenges for clinical care of an ageing population infected with HIV: a modelling study Dr Mikaela Smit, PhD, Kees Brinkman, MD, Suzanne Geerlings,
Advertisements

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker  Kyaw M Tun, MD, Dr Mallika Imwong,
Effects of vector-control interventions on changes in risk of malaria parasitaemia in sub- Saharan Africa: a spatial and temporal analysis  Federica Giardina,
Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam  Mallika Imwong, Tran T Hien, Nguyen T Thuy-Nhien, Arjen M Dondorp,
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and.
Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 
Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled,
Volume 386, Issue 9992, Pages (August 2015)
Estimated need for surgery worldwide based on prevalence of diseases: a modelling strategy for the WHO Global Health Estimate  John Rose, MD, Thomas G.
Volume 369, Issue 9563, Pages (March 2007)
Volume 382, Issue 9902, Pages (October 2013)
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection  Dr Mihály Sulyok,
Volume 15, Issue 10, Pages (September 2014)
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum.
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial 
Association between particular polymorphic residues on apical membrane antigen 1 (AMA-1) and platelet levels in patients with vivax malaria  P. Grynberg,
Volume 14, Issue 4, Pages (April 2015)
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study  Dr R McGready,
R. Cantón  Clinical Microbiology and Infection 
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study 
Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study  Kerryn A Moore, MSc, Julie A Simpson, PhD, Moo.
Ebola: worldwide dissemination risk and response priorities
The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study  Thuy-Nhien.
Future challenges for clinical care of an ageing population infected with HIV: a modelling study  Dr Mikaela Smit, PhD, Kees Brinkman, MD, Suzanne Geerlings,
Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study  Helen Booth, MSc, Omar Khan, FRCS, Prof Toby Prevost, PhD,
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study 
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection  Dr Mihály Sulyok,
Effects of a parenting intervention to address maternal psychological wellbeing and child development and growth in rural Uganda: a community-based, cluster-randomised.
Volume 382, Issue 9902, Pages (October 2013)
Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam  Mallika Imwong, Tran T Hien, Nguyen T Thuy-Nhien, Arjen M Dondorp,
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised,
Estimated need for surgery worldwide based on prevalence of diseases: a modelling strategy for the WHO Global Health Estimate  John Rose, MD, Thomas G.
Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study  Kerryn A Moore, MSc, Julie A Simpson, PhD, Moo.
Volume 15, Issue 6, Pages (May 2014)
Volume 379, Issue 9830, Pages (May 2012)
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta- analysis  Prof Ric N Price, MD, Lorenz von Seidlein, PhD, Neena.
Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 
Low-level lead exposure and mortality in US adults: a population-based cohort study  Prof Bruce P Lanphear, MD, Stephen Rauch, MPH, Peggy Auinger, MS,
Effect of a knowledge-based and skills-based programme for physicians on risk of sexually transmitted reinfections among high-risk patients in China:
Malaria burden and costs of intensified control in Bhutan, 2006–14: an observational study and situation analysis  Kinley Wangdi, MSc, Cathy Banwell,
Health consequences of exposure to e-waste: a systematic review
Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark  Dr Bethan Davies, PhD, Katy.
Global feasibility assessment of interrupting the transmission of soil-transmitted helminths: a statistical modelling study  Prof Simon J Brooker, DPhil,
Volume 386, Issue 9992, Pages (August 2015)
Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis  Robert J Commons, FRACP, Prof Julie.
Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker  Kyaw M Tun, MD, Dr Mallika Imwong,
Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis  Dr Robert W Aldridge, MSc,
Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled,
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study  Prof Daniel Kotz, PhD, Wolfgang Viechtbauer, PhD, Colin Simpson,
Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study  Dr Patrick.
Individual-level factors associated with the risk of acquiring human Plasmodium knowlesi malaria in Malaysia: a case-control study  Dr Matthew J Grigg,
Effects of vector-control interventions on changes in risk of malaria parasitaemia in sub- Saharan Africa: a spatial and temporal analysis  Federica Giardina,
Volume 373, Issue 9663, Pages (February 2009)
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual.
Volume 3, Issue 1, Pages (January 2016)
Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial  Dr.
Volume 386, Issue 10005, Pages (October 2015)
Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study  Sabin Nsanzimana, MD, Eric Remera, MSc, Steve Kanters,
Global economic consequences of selected surgical diseases: a modelling study  Dr Blake C Alkire, MD, Mark G Shrime, MD, Anna J Dare, PhD, Prof Jeffrey.
Incidence and severity of childhood pneumonia in the first year of life in a South African birth cohort: the Drakenstein Child Health Study  Dr David.
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational.
The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study  Dr Mallika Imwong,
Volume 2, Issue 10, Pages (October 2015)
Artefenomel: a promising new antimalarial drug
Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and.
The Lancet Infectious Diseases
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum.
A probiotic trial: tipping the balance of evidence?
Presentation transcript:

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial  Aung Pyae Phyo, MD, Podjanee Jittamala, MD, Prof François H Nosten, PhD, Prof Sasithon Pukrittayakamee, MD, Mallika Imwong, PhD, Prof Nicholas J White, FRS, Stephan Duparc, MD, Fiona Macintyre, PhD, Mark Baker, PhD, Dr Jörg J Möhrle, PhD  The Lancet Infectious Diseases  Volume 16, Issue 1, Pages 61-69 (January 2016) DOI: 10.1016/S1473-3099(15)00320-5 Copyright © 2016 Phyo et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 1 Study flow diagram A new dose (cohort) was initiated after review of the findings from the preceding cohort. During the 36 h study period, parasitaemia, artefenomel exposure, and other variables were assessed. Definitive treatment to cure malaria involved standard drugs (mefloquine plus artesunate or chloroquine plus primaquine) and was given to avoid recrudescence. Patients infected with Plasmodium falciparum and Plasmodium vivax followed the same clinical protocols. The Lancet Infectious Diseases 2016 16, 61-69DOI: (10.1016/S1473-3099(15)00320-5) Copyright © 2016 Phyo et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 2 Parasite counts after treatment start per protocol set Patients with (A) Plasmodium falciparum and (B) Plasmodium vivax. Blue lines show individual patient curves before rescue treatment (one patient in 200 mg cohort). The red line represents the median. The Lancet Infectious Diseases 2016 16, 61-69DOI: (10.1016/S1473-3099(15)00320-5) Copyright © 2016 Phyo et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 3 Parasite clearance and kelch mutations Clearance times for patients infected with parasites with kelch mutations or wild-type. The horizontal line represents the median. The Lancet Infectious Diseases 2016 16, 61-69DOI: (10.1016/S1473-3099(15)00320-5) Copyright © 2016 Phyo et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions